These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 9402265)

  • 1. Effect of disruption versus continuation of gonadotrophin-releasing agonist after human chorionic gonadotrophin administration on corpus luteum function in patients undergoing ovulation induction for in-vitro fertilization.
    Valbuena D; Pellicer A; Guanes PP; Remohí J; Simón C
    Hum Reprod; 1997 Oct; 12(10):2118-22. PubMed ID: 9402265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization.
    Beckers NG; Laven JS; Eijkemans MJ; Fauser BC
    Hum Reprod; 2000 Jan; 15(1):43-9. PubMed ID: 10611186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The benefits of mid-luteal addition of human chorionic gonadotrophin in in-vitro fertilization using a down-regulation protocol and luteal support with progesterone.
    Herman A; Raziel A; Strassburger D; Soffer Y; Bukovsky I; Ron-El R
    Hum Reprod; 1996 Jul; 11(7):1552-7. PubMed ID: 8671503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles.
    Peñarrubia J; Balasch J; Fábregues F; Creus M; Casamitjana R; Ballescá JL; Puerto B; Vanrell JA
    Hum Reprod; 1998 Dec; 13(12):3315-8. PubMed ID: 9886506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of gonadotrophin-releasing hormone agonists administered as desensitizing or flare protocols on hormonal function in the luteal phase of hyperstimulated cycles.
    Norman RJ; Warnes GM; Wang X; Kirby CA; Matthews CD
    Hum Reprod; 1991 Feb; 6(2):206-13. PubMed ID: 1905309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Titrating luteinizing hormone surge requirements for ovulatory changes in primate follicles. I. Oocyte maturation and corpus luteum function.
    Zelinski-Wooten MB; Lanzendorf SE; Wolf DP; Chandrasekher YA; Stouffer RL
    J Clin Endocrinol Metab; 1991 Sep; 73(3):577-83. PubMed ID: 1908481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effect of exogenous human chorionic gonadotrophin on progesterone production from normal or malfunctioning corpus luteum.
    Momoeda M; Tsutsumi O; Morita Y; Igarashi T; Suenaga A; Osuga Y; Shiotsu H; Yano T; Taketani Y
    Hum Reprod; 1998 Jul; 13(7):1907-11. PubMed ID: 9740447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luteal phase support in in-vitro fertilization using gonadotrophin releasing hormone analogue before ovarian stimulation: a prospective randomized study of human chorionic gonadotrophin versus intramuscular progesterone.
    Claman P; Domingo M; Leader A
    Hum Reprod; 1992 Apr; 7(4):487-9. PubMed ID: 1522190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin.
    Fraser HM; Nestor JJ; Vickery BH
    Endocrinology; 1987 Aug; 121(2):612-8. PubMed ID: 3109885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study.
    Humaidan P; Bungum L; Bungum M; Yding Andersen C
    Reprod Biomed Online; 2006 Aug; 13(2):173-8. PubMed ID: 16895629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
    Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
    Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Premature luteinization is not eliminated by pituitary desensitization with leuprolide acetate in women undergoing gonadotrophin stimulation who demonstrated premature luteinization in a prior gonadotrophin-only cycle.
    Hofmann GE; Bergh PA; Guzman I; Masuku S; Navot D
    Hum Reprod; 1993 May; 8(5):695-8. PubMed ID: 8314961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recovery of corpus luteum function after prolonged deprivation from gonadotrophin stimulation.
    Weissman A; Loumaye E; Shoham Z
    Hum Reprod; 1996 May; 11(5):943-9. PubMed ID: 8671368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix.
    Tavaniotou A; Albano C; Smitz J; Devroey P
    Hum Reprod; 2001 Apr; 16(4):663-7. PubMed ID: 11278214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human chorionic gonadotrophin is a better luteal support than progesterone in ultrashort gonadotrophin-releasing hormone agonist/menotrophin in-vitro fertilization cycles.
    Golan A; Herman A; Soffer Y; Bukovsky I; Caspi E; Ron-El R
    Hum Reprod; 1993 Sep; 8(9):1372-5. PubMed ID: 8253920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated GnRH agonist doses for luteal support: a proof of concept.
    Wiser A; Klement AH; Shavit T; Berkovitz A; Koren RR; Gonen O; Amichay K; Shulman A
    Reprod Biomed Online; 2019 Nov; 39(5):770-776. PubMed ID: 31628035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.